Southeastern coach lymphoma free

Southeastern Louisiana college football coach Dennis Roland, 49, who was diagnosed with non-Hodgkin's lymphoma in May, says he has been told that he's cancer-free. "I've got two more rounds of treatment that I had been mentally putting off," said Roland, "But now I know I can go in and knock them off."



The first three chemotherapy sessions reduced the cancer by 80 percent and the second three, the last of which was completed last week, finished the process. "It leaves my feet numb and just feeling beat down and weak in general," Roland said of the treatments. "Its not a cakewalk for anybody. It beats the alternative, though."




Because of the treatments, Roland, who had a full-head of hair, is bald. "Im anxious for it to grow back," he said. "But I am afraid of what color its going to be."



Roland, in his first year as the Lions head coach, said he never thought of relinquishing his duties. "There are always a lot of things that go through your mind when youre in the hospital," he said. "But I was always encouraged to stay on."

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap